Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can mindfulness rewire teen brains to curb vaping?

NCT ID NCT06503159

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a mindfulness training program could change brain connections in teenagers who vape tobacco. Researchers used brain scans to see if these changes were linked to less vaping. The study was small and ended early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

May 2025

Finished

Sep 2025

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: Non-Vaping group: 1. For adolescents aged 17 and under, parental/guardian informed consent to participate in the study 2. English language fluency 3. Males and females; Age 13-18 enrolled in grades 9-12, or the summer after graduation. 4. No MRI contraindications 5. No evidence of current psychosis, mania, or significant suicidality 6. If on medication for depression, anxiety or ADHD, dose has been stable for 3 months 7. No DSM-5 diagnosis of moderate or severe substance use disorder (SUD) related to a psychoactive substance, including tobacco, in the past year 8. Access to necessary resources for participating in a technology-based intervention, which includes smartphone ownership for this study 9. No use of nicotine more than five (5) times in their life, and none at all in the last 30 days prior to enrollment. Vaping group: 1. For adolescents aged 17 and under, parental/guardian informed consent to participate in the study 2. English language fluency 3. Males and females; Age 13-18 enrolled in grades 9-12, or the summer after graduation. 4. No MRI contraindications 5. No evidence of current psychosis, mania, or significant suicidality 6. If on medication for depression, anxiety or attention deficit hyperactivity disorder (ADHD), dose has been stable for 3 months 7. No Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of moderate or severe SUD related to another psychoactive substance (other than tobacco) in the past year 8. Vape a nicotine containing product at least 10 days in the past 30 days 9. Access to necessary resources for participating in a technology-based intervention, which includes smartphone ownership for this study EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study based on self and or parent-report unless otherwise noted: Vaping or Non-Vaping Group: 1. Chronic medical conditions associated with cerebral blood flow abnormalities per PI/MAI determination after review of the medical history. 2. Neurological conditions that may interfere with MRI data quality per PI/MAI determination after review of the medical history. 3. Neurodevelopmental disorders that are likely to significantly affect data in the judgment of the MAI/PI 4. Non-penetrating traumatic brain injury with loss of consciousness \> 30 minutes or significant sequelae persisting longer than two weeks or any penetrating traumatic brain injury. 5. Changing dose of psychotropic medication in past three months 6. Current regular meditation or yoga practice averaging \>10 min/day for \>2 days per week 7. Pregnancy, self-report upon protocol entry, but by urine test prior to MRI scan.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Vaping

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institute on Drug Abuse

    Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.